A method of treating ERα positive cancer comprising administering to a patient in need thereof an effective amount of a small molecule inhibitor or a pharmaceutically acceptable salt thereof, wherein the small molecule inhibitor acts through estrogen receptor a and activates one or more of the three arms of the unfolded protein response pathway (UPR) is provided.